ESC 2017

Episodes 17-23 of 23

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective
Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective
ESC 2017
Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective
Natural randomisation shows that mode of LDL-lowering determines CV benefit
Natural randomisation shows that mode of LDL-lowering determines CV benefit
ESC 2017
Natural randomisation shows that mode of LDL-lowering determines CV benefit
NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors
NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors
ESC 2017
NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors
Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients
Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients
ESC 2017
Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients
NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD
NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD
ESC 2017
NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD
Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk
Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk
ESC 2017
Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk
A new challenge for precision medicine: selecting major contributing risk factors
A new challenge for precision medicine: selecting major contributing risk factors
ESC 2017
A new challenge for precision medicine: selecting major contributing risk factors

2/2

Episodes 17-23 of 23

Title

Share on ReachMD